100 research outputs found
Lung cancer and Toll-like receptors.
Lung carcinoma is one of the leading causes of death worldwide. It is a non-immunogenic cancer, resistant to immune surveillance. Toll-like receptors (TLRs) connect the innate to the adaptive immune system. Given that cancerous cells evade the immune system, the activation of TLRs could represent a potential target for cancer therapy. The induction of Th1-like and cytotoxic immunity by TLR signalling could lead to tumour cell death, resulting in tumour regression or arrest. However, basic research and clinical trials revealed that the activation of specific TLRs, such as TLR2, TLR4 and TLR9, do not have any anti-tumour activity in lung carcinoma. Increasing evidence suggests that TLRs are important regulators of tumour biology; however, little is known about their function in lung cancer. Thus, in order to develop new therapeutic approaches, further studies are needed to understand the connection between TLRs and lung cancer progression. This review focuses on the potential mechanisms by which TLR ligands can facilitate or not lung cancer and lung metastases establishment/progression
Plasmacytoid Dendritic Cells: From Heart to Vessels
Cardiovascular diseases, formerly only attributed to the alterations of the stromal component, are now recognized as immune-based pathologies.
Plasmacytoid Dendritic Cells (pDCs) are important immune orchestrators in heart and vessels. They highly produce IFN type I that promote the polarization of T cells towards a Th1 phenotype; however, pDCs can also participate to suppressive networks via the recruitment of T regulatory cells that downmodulate proinflammatory responses.
pDCs populate the vessel wall layers during pathological conditions, such as atherosclerosis. It is thus clear that a better identification of pDCs activity in cardiovascular diseases can not only elucidate pathological mechanisms but also lead to new therapeutic approaches
Preliminary analysis of genetic variation of Escallonia alpina and E. rubra
Escallonia alpina y E. rubra (Escalloniaceae) comparten su área de distribución en el sur de los Andes y se diferencian por pocos caracteres morfológicos diagnósticos, tales como la disposición de las flores y la presencia y tipo de glándulas; sin embargo, en algunas poblaciones no es posible asignar los individuos a una u otra especie. Además, se han reconocido y descrito como híbridos varias formas de transición entre ambas. El objetivo de este trabajo es examinar la variabilidad genética poblacional de Escallonia alpina y E. rubra, y analizar si se corresponde con la variabilidad morfológica observada. Se estudió la morfología en 39 individuos de cinco poblaciones sobre los que también se realizó un análisis de AFLP. Se investigó la relación entre los individuos mediante análisis de ordenación, agrupamiento y de asignación bayesiana. Además se calcularon índices de diversidad y se realizó una prueba de Mantel. A partir del análisis morfológico, se asignaron dos poblaciones a cada especie, mientras que una población con individuos con morfología intermedia no se pudo asignar unívocamente a ninguna de las dos especies. Se observó una fuerte correspondencia entre las especies delimitadas mediante caracteres morfológicos diagnósticos tradicionales y el patrón de AFLP. La evidencia morfológica y molecular preliminar nos permitió reconocer a Escallonia alpina y E. rubra como dos especies distintas, y a una población con caracteres morfológicos y genéticos intermedios que podrían ser el resultado de flujo génico interespecífico o de una separación incompleta de linajes.Escallonia alpina and E. rubra (Escalloniaceae) are distributed in the same geographical region in the southern Andes; they are differentiated by few diagnostic morphological characters such as flower arrangement, and type and presence of glands. A morphological gap between both species is absent in some populations; in addition, intermediate forms have been recognized and described as hybrids. The aim of this work is to examine the genetic variation in populations of Escallonia alpina and E. rubra, and to analyze if there is a correspondence between genetic and morphological variability. We studied the morphology of 39 individuals belonging to five populations, which were also used to perform an AFLP analysis. We conducted ordination, clustering and Bayesian assignment analyses to investigate the relationship among individuals, and we calculated genetic diversity indices and a Mantel test. As a result of the morphological analysis, two populations were assigned to each species, while the remaining population could not be assigned unequivocally to any of the two species, as the individuals exhibited an intermediate morphology. A strong correspondence between traditional morphological characters and the AFLP pattern was observed. Our preliminary morphological and molecular evidence support Escallonia alpina and E. rubra as two distinct species. The variability found in the intermediate population might be the result of inter-specific hybridization or incomplete lineage sorting.Fil: Morello, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Botánica Darwinion (i); Argentina;Fil: Giussani, Liliana Monica. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Botánica Darwinion (i); Argentina;Fil: Sede, Silvana Mabel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Botánica Darwinion (i); Argentina
Thrombo-Inflammation: A Focus on NTPDase1/CD39
There is increasing evidence for a link between inflammation and thrombosis. Following
tissue injury, vascular endothelium becomes activated, losing its antithrombotic properties whereas
inflammatory mediators build up a prothrombotic environment. Platelets are the first elements to be
activated following endothelial damage; they participate in physiological haemostasis, but also in
inflammatory and thrombotic events occurring in an injured tissue. While physiological haemostasis
develops rapidly to prevent excessive blood loss in the endothelium activated by inflammation,
hypoxia or by altered blood flow, thrombosis develops slowly. Activated platelets release the content
of their granules, including ATP and ADP released from their dense granules. Ectonucleoside
triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP,
which in turn, is hydrolysed to adenosine by ecto-50
-nucleotidase (CD73). NTPDase1/CD39 has
emerged has an important molecule in the vasculature and on platelet surfaces; it limits thrombotic
events and contributes to maintain the antithrombotic properties of endothelium. The aim of the
present review is to provide an overview of platelets as cellular elements interfacing haemostasis
and inflammation, with a particular focus on the emerging role of NTPDase1/CD39 in controlling
both processes
Polyinosinic-polycytidylic Acid limits tumor outgrowth in a mouse model of metastatic lung cancer.
Polyinosinic-polycytidylic acid (poly I:C), a TLR3 ligand, is currently being tested in human clinical trials as an adjuvant to anti-cancer vaccines and in combination with other therapies. However, little is known about its activity in established pulmonary metastasis. The aim of our study was to elucidate the effect of poly I:C (1, 10, or 100 μg/mouse) in a mouse model of B16-F10-induced metastatic lung cancer. Lung tumor growth was arrested after a single administration of poly I:C. This was associated with higher influx of mature dendritic cells (DCs), which drove toward a Th1-like, Th17-like, and cytotoxic immune environment. The interference with IFN type I receptor signaling by means of a specific mAb reversed poly I:C-mediated tumor regression due to lower presence of myeloid DCs, cytotoxic DCs (CD11c(+)CD8(+)), NKT cells, CD8(+) T cells, and Th1-like cytokines. Moreover, the adoptive transfer of poly I:C-activated bone marrow-derived DCs into tumor-bearing mice resulted in activities similar to those of the systemic administration of poly I:C on lung tumor burden. In conclusion, our data prove that poly I:C has potential anti-tumor activity in a mouse model of established pulmonary metastasis. The activation of DCs and the production of IFN type I are responsible for an effective T cytotoxic immune response against metastatic lung cancer progression after poly I:C treatment
Role of Intracellular and Extracellular Annexin A1 in MIA PaCa-2 Spheroids Formation and Drug Sensitivity
Simple Summary In order to improve the investigation of pancreatic cancer (PC), often supported through analyzes two-dimensional (2D) cell monolayers, we proposed to create a spheroid-based in vitro three-dimensional (3D) model using wild-type (WT) and ANXA1 knock-out (KO) MIA PaCa-2 PC cells. However, the production of spheroids still represents a technical challenge. Here, we have developed a protocol to obtain well-organized spheroids and have proved that Annexin A1 (ANXA1) affects the spheroid formation, because the WT cells have a greater ability to form this 3D model when compared to the ANXA1 KO examples. We also investigated how ANXA1 action could influence the PC pharmacological response both in basal conditions and by mimicking a tumor system through the addition of autocrine EVs. ANXA1, via EVs, significantly improves the formation, the stability and the drug resistance of this model, particularly compared to the ANXA1 KO one, which shows a structural instability and a greater drug sensitivity. Among solid tumors, pancreatic cancer (PC) remains a leading cause of death. In PC, the protein ANXA1 has been identified as an oncogenic factor acting in an autocrine/paracrine way, and also as a component of tumor-deriving extracellular vesicles. Here, we proposed the experimental protocol to obtain spheroids from the two cell lines, wild-type (WT) and Annexin A1 (ANXA1) knock-out (KO) MIA PaCa-2, this last previously obtained through CRISPR/Cas9 genome editing system. The use of three-dimensional (3D) models, like spheroids, can be useful to mimic tumor characteristics and for preclinical chemo-sensitivity studies. By using PC spheroids, we have assessed the activity of intracellular and extracellular ANXA1. Indeed, we have proved that the intracellular protein influences in vitro tumor development and growth by spheroids analysis, in addition to defining the modification about cell protein pattern in ANXA1 KO model compared to the WT one. Moreover, we have tested the response to FOLFIRINOX chemotherapy regimen whose cytostatic effect appeared notably increased in ANXA1 KO spheroids. Additionally, this study has highlighted that the extracellular ANXA1 action is strengthened through the EVs supporting spheroids growth and resistance to drug treatment, mainly affecting tumor progression. Thus, our data interestingly suggest the relevance of ANXA1 as a potential therapeutic PC marker
Cl-IB-MECA Inhibits Human Thyroid Cancer Cell Proliferation Independently of A3 Adenosine Receptor Activation
A3 adenosine receptor (A3AR) agonists have been reported to modulate cellular proliferation. This work was aimed to investigate the expression and the possible implication of A3AR in the human thyroid carcinomas. Normal thyroid tissue samples did not express A3 adenosine receptor, while primary thyroid cancer tissues expressed high level of A3AR, as determined by immunohistochemistry analysis. In human papillary thyroid carcinoma cell line, NPA, at concentrations > or =10 microM, the A3AR-selective agonist 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) produced inhibition of cell growth, by blocking the G(1) cell cycle phase in a concentration- and time-dependent manner. This effect was well correlated with a reduction of protein expression of cyclins D1 and E2 after 24 hours of Cl-IB-MECA treatment. Moreover Cl-IB-MECA induced dephosphorylation of ERK1/2 in a time- and concentration-dependent manner, which in turn inhibits cell proliferation. The effect of Cl-IB-MECA was not prevented by A3AR antagonists, MRS1191 or MRS1523 or FA385. Furthermore, neither nucleoside transporter inhibitors, Dypiridamole and NBTI, nor the A1, A2A and A2B receptors antagonists were able to block the response to Cl-IB-MECA. Although Cl-IB-MECA has been shown to influence cell death and survival in other systems through an A3AR-mediated mechanism, in NPA cells the growth inhibition induced by micromolar concentrations of Cl-IB-MECA is not related to A3AR activation and hence that its effects on human papillary carcinoma cell line seem to be independent of the presence of this receptor subtype
Lack of Ecto-5'-Nucleotidase Protects Sensitized Mice against Allergen Challenge
Ecto-5'-nucleotidase (CD73), the ectoenzyme that together with CD39 is responsible for extracellular ATP hydrolysis and adenosine accumulation, regulates immune/inflammatory processes by controlling innate and acquired immunity cell functions. We previously demonstrated that CD73 is required for the assessment of a controlled allergic sensitization, in mice. Here, we evaluated the response to aerosolized allergen of female-sensitized mice lacking CD73 in comparison with their wild type counterpart. Results obtained show, in mice lacking CD73, the absence of airway hyperreactivity in response to an allergen challenge, paralleled by reduced airway CD23+B cells and IL4+T cells pulmonary accumulation together with reduced mast cells accumulation and degranulation. Our findings indicate CD73 as a potential therapeutic target for allergic asthma
Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways
Triple negative breast cancer (TNBC) patients have high risk of recurrence and metastasis, and current treatment options remain limited. Cancer stem-like cells (CSCs) have been linked to cancer initiation, progression and chemotherapy resistance. Notch signaling is a key pathway regulating TNBC CSC survival. Treatment of TNBC with PI3K or mTORC1/2 inhibitors results in drug-resistant, Notch-dependent CSC. However, downstream mechanisms and potentially druggable Notch effectors in TNBC CSCs are largely unknown. We studied the role of the AKT pathway and mitochondrial metabolism downstream of Notch signaling in TNBC CSC from cell lines representative of different TNBC molecular subtypes as well as a novel patient-derived model. We demonstrate that exposure of TNBC cells to recombinant Notch ligand Jagged1 leads to rapid AKT phosphorylation in a Notch1-dependent but RBP-Jκ independent fashion. This requires mTOR and IKKα. Jagged1 also stimulates mitochondrial respiration and fermentation in an AKT- and IKK-dependent fashion. Notch1 co-localizes with mitochondria in TNBC cells. Pharmacological inhibition of Notch cleavage by gamma secretase inhibitor PF-03084014 in combination with AKT inhibitor MK-2206 or IKK-targeted NF-κB inhibitor Bay11-7082 blocks secondary mammosphere formation from sorted CD90hi or CD44+CD24low (CSCs) cells. A TNBC patient-derived model gave comparable results. Besides mitochondrial oxidative metabolism, Jagged1 also triggers nuclear, NF-κB-dependent transcription of anti-apoptotic gene cIAP-2. This requires recruitment of Notch1, IKKα and NF-κB to the cIAP-2 promoter. Our observations support a model where Jagged1 triggers IKKα-dependent, mitochondrial and nuclear Notch1 signals that stimulate AKT phosphorylation, oxidative metabolism and transcription of survival genes in PTEN wild-type TNBC cells. These data suggest that combination treatments targeting the intersection of the Notch, AKT and NF-κB pathways have potential therapeutic applications against CSCs in TNBC cases with Notch1 and wild-type PTEN expression
Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells
Emerging evidence suggests that the adenosine A2b receptor (ADORA2B, also known as A2bR) plays a pivotal role in tumor progression. We have recently demonstrated that blocking A2bR stimulates T cell-mediated immunosurveillance in a melanoma model by impairing the influx of myeloid-deriver suppressor cells (MDSCs) into the tumor microenvironment. This results in robust antineoplastic effects, which can be abrogated by the adoptive transfer of MDSCs
- …